We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

RYAM:NYSERayonier Advanced Materials Inc. Analysis

Data as of 2026-04-29 - not real-time

$9.90

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Rayonier Advanced Materials is trading near the 20‑day simple moving average, which sits just below the 50‑day average, indicating a marginally bearish tilt. The 14‑day RSI hovers around the midpoint, suggesting neutral momentum, while the MACD histogram is negative, confirming short‑term bearish pressure. Price action remains bounded between a clear support level near $8.15 and resistance around $11.38, with the current market price modestly above the support floor. Volatility is elevated at roughly 65% over the past 30 days and a beta exceeding 2 signals heightened sensitivity to market swings. Fundamentally, the company posts a forward PE of about 8.4, a low price‑to‑sales multiple, and a target price of $14.50, implying upside potential of over 40% despite negative trailing earnings and sizable debt. The balance sheet is leveraged (debt‑to‑equity > 200%) and free cash flow is negative, raising concerns about cash sustainability. In the context of extreme market greed (Fear & Greed Index > 80), investors may be tempted by the upside, but the underlying earnings weakness and high leverage temper enthusiasm. The sector—basic materials chemicals—carries medium‑level cyclical and regulatory exposure, amplified by the company's global footprint across North America, Europe, and Asia. Currency exposure is modest, as revenues are primarily USD‑denominated, but geographic diversification adds a layer of medium risk. Overall, the stock sits at a crossroads where technical weakness clashes with a valuation that suggests it may be undervalued relative to its long‑term earnings potential.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bearish MACD and neutral RSI signal limited upside in the near term
  • Price is near support but still above key floor, limiting downside risk
  • High volatility and beta increase short‑term price uncertainty

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Forward earnings estimate turns positive, supporting valuation uplift
  • Target price suggests >40% upside from current levels
  • Improving market sentiment (extreme greed) may drive price toward upside

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Undervalued relative to forward PE and price‑to‑sales multiples
  • Strategic positioning in specialty cellulose markets offers growth tailwinds
  • Long‑term structural demand for bio‑based materials underpins fundamentals

Key Metrics & Analysis

Financial Health

Revenue Growth-1.20%
Profit Margin-28.69%
P/E Ratio8.4
ROE-80.43%
ROA0.39%
Debt/Equity245.74
P/B Ratio2.1
Op. Cash Flow$23.9M
Free Cash Flow$-75546000

Technical Analysis

TrendNeutral
RSI50.3
Support$8.15
Resistance$11.38
MA 20$9.84
MA 50$9.96
MA 200$7.24
MACDBearish
VolumeIncreasing
Fear & Greed Index89.59

Valuation

Target Price$14.50
Upside/Downside46.46%
GradeUndervalued
TypeValue

Risk Assessment

Beta2.12
Volatility65.31%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.